Two Biotechnology Stocks Trading Higher Today: Capricor Therapeutics and RedHill Biopharma

Biotechnology

If you’re looking for a particular industry to start investing in, why not consider the healthcare industry? Sure, cryptocurrency or technology might be a tad bit more exciting, but let us not forget that the healthcare sector plays a crucial role in the economy of whatever country we reside in. Plus, there are a number of stocks within the healthcare industry to choose from, like biotechnology stocks.

Think of it this way: cryptocurrency and online giants like Apple (NASDAQ:AAPL) might not be around forever. However, I can almost guarantee that the healthcare sector will be.

Have I convinced you to add some healthcare or biotechnology stocks to your investment portfolio? No? Well, how about this: currently, there are two biotechnology stocks on the rise, while bitcoin has dropped back down to $10,889 today and Apple is trading down 0.20%. Out of these options, what would you choose? Personally, I would rather focus some time on learning about the stocks that are seeing green.

That said, there are a number of technology stocks that are trading higher today, like Twitter (NYSE:TWTR) who is up nearly 10%. However, I think diversity in an investment portfolio is what makes an investor successful. So, without further adieu, let’s look at two biotechnology stocks jumping today.

Additional Biotechnology news >>

Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics is a clinical-stage biotechnology company based in Beverly Hills, California. Under the leadership of Linda Marban, Capricor Therapeutics focuses primarily on developing products that can be used to treat cardiovascular diseases. Currently, the healthcare company has a market capitalization of 54.25 million.

At the time of writing, Capricor Therapeutics is trading at $2.12, putting the CAPR stock up $0.43, or 25.44%. Considering the market still has a couple hours of life left in it, and the fact that Capricor hasn’t actually announced anything that would indicate a jump in price, it will be interesting to see where the stock is at when the closing bell rings.

Though the California based company hasn’t announced anything today, the jump might have been caused by investor optimism. Why? Because Capricor has had a relatively successful couple of months. From announcing on December 13 the issuance of key U.S. patent on exosome technology to announcing last week that it has added a number of new patent applications to its Exclusive License Agreement with Cedars-Sinai Medical Center, I can see why investors are so excited about this stock.

The latter announcement might be one of the main reasons the stock is jumping today. Under the terms of the agreement, Capricor Therapeutics will be granted exclusive global rights to commercially create and market CDCs.

More Biotechnology News >>

RedHill Biopharma Ltd. (NASDAQ:RDHL)

Currently, RedHill Biopharma is trading at $6.43, which puts the stock up $0.86, or 15.44%.

Based in Israel, RedHill Biopharma is a biopharmaceutical company that focuses on both developing and marketing drugs that can be used to treat cancer and gastrointestinal diseases. In the United States, RedHill has two main gastrointestinal products in the United States.

Similar to Capricor, RedHill Biopharma hasn’t announced anything today that would explain a nearly 20% jump. However, like Capricor, RedHill has made numerous announcements this month, which could be one explanation for today’s jump. For instance, on January 16, the company posted its final results from one of its phase 2 studies. The next day, RedHill Biopharma announced that EnteraGam was added to its Inside Rx prescription savings program.

Featured Image: AZPain